 characterization of SET/I2PP2A Isoforms in Dogs

Ryotaro YABE1, Nobuyuki FUJWARA1, Takuya MIZUNO2, Tatsuya USUI3, Takashi OHAMA1* and Koichi SATO1

1) Laboratory of Veterinary Pharmacology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753–8515, Japan
2) Laboratory of Veterinary Clinical Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753–8515, Japan
3) Laboratory of Veterinary Toxicology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753–8515, Japan

(Received 25 April 2014/Accepted 15 May 2014/Published online in J-STAGE 3 June 2014)

ABSTRACT. SET is an endogenous protein phosphatase 2A (PP2A) inhibitor and is associated with a poor prognosis in human leukemia. Previously, we reported increased SET protein levels in canine lymphoma cell lines and the potential therapeutic application of SET antagonists in canine lymphoma. Here, we found that canine cells express several isoforms of the SET protein. We cloned 4 isoforms of SET, named SETα, β, γ and δ. Genomic BLAST showed that the SET genes are located on chromosomes X, 7, 1 and 8, respectively. An immunofluorescent study showed nuclear localization of SETα and β, and nuclear and cytosolic localization of SETγ and δ. We confirmed that SETα and β possess the ability to associate with PP2A. Our data reveal the existence of unique SET isoforms that should be taken into account in SET-targeting drug development studies in dogs.

KEY WORDS: cancer, canine, phosphorylation, protein phosphatase 2A, SET/I2PP2A

©2014 The Japanese Society of Veterinary Science
decl: 10.1292/jvms.14-0209; J. Vet. Med. Sci. 76(9): 1235–1240, 2014
36-mer oligonucleotide 5′-CTTTGTAGTCGGATCCTGGAATCCATCAGTGTTCCA-3′ were designed as the 5′ primer and the 3′ primer, respectively, to sequence canine SET variants. PfuUltra II (Life Technologies) was used for the PCR amplification, which was conducted with 40 cycles of 20 sec at 95°C, 20 sec at 60°C and 60 sec at 72°C. The PCR products were cloned into pLVSIN-EF1α-IRES-ZsGreen Vector (Takara, Tokyo, Japan) by InFusion (Takara), according to the manufacturer’s instructions. Plasmids were sequenced using BigDye Terminator v3.1 cycle sequencing kit and ABI3130 sequencer (Life technologies). Plasmids were transfected into cells using Polyethylenimine Max (Polysciences, Taipei, Taiwan), according to the manufacturer’s instructions.

**RESULTS**

To examine the protein expression of SET isoforms in canine cells, normal peripheral blood mononuclear cells (PBMC), melanoma cell lines CMeC1, CMeC2, KMeC and LMeC, lymphoma cell line Ema and the renal tubule epithelial cell line MDCK were lysed for immunoblotting. The major bands were observed around 37 kDa by 2 types of anti-SET antibodies against 3–18 aa of human SETα (N-term) and 175–215 aa of human SETα (Middle). The minor bands were commonly observed around 25 kDa by the 2 antibodies. Only anti-SETα (Middle) detected the major band around 50 kDa and weak bands around 15 kDa. These data indicate that canine cells express more than one SET isoform (Fig. 1).

To determine the sequence of canine SET isoforms, we cloned the protein cDNA from the Beagle thymus, as described in the Materials and Methods. Interestingly, the same primer isolated 4 types of cDNA sequences. cDNA sequences for 4 isoforms, named α, β, γ and δ, were aligned using Clustal X2 (Fig. 2). Genomic BLAST (Basic Local Alignment Search Tool) revealed that isoform α, β, γ and δ genes are 99% homologous to CanFem3.1 whole shotgun sequences NW_003726126.1, NW_003726067.1, NW_003726047.1 and NW_003726071.1 and are located on chromosomes X, 7, 1 and 8, respectively. Isoform α expresses 290 aa protein, which is the same size as human SETα. Alignment of the protein sequences of human SETα and canine SETα revealed that approximately 94% were homologous between the 2 species (Fig. 3A). In contrast, isoforms β, γ and δ have a single base insertion and express 223 aa, 112 aa and 102 aa C-terminus truncated SET proteins, respectively (Figs. 2 and 3B).

To examine whether canine SET isoforms are conformationally stable, HEK293T cells were transfected to express the canine SET isoforms, and protein levels were determined by immunoblotting (Fig. 4A). The anti-FLAG antibody detected the bands around 52 kDa for FLAgx3-SETα, around 37 kDa for FLAgx3-SETβ, around 24 kDa for FLAgx3-SETγ and around 20 kDa for FLAgx3-SETδ. Although these bands are much higher than the predicted size of canine SETα, β, γ and δ, which are 33.5 kDa, 26.1 kDa, 12.6 kDa and 11.9 kDa, respectively, a similar upper shift was also observed for human SETα with FLAGx3 tag (Data not shown). Next, we examined the localization of canine SET isoforms.
Both anti-SET (N-term) and anti-SET (Middle) antibodies exhibited nuclear localization of the endogenous canine SET in CMeC1 cells (Fig. 4B). To determine the localization of individual isoforms, HEK293T cells were transfected to express canine SET isoforms. pLVSIN-EF1α-IRES-ZsGreen canines SET isoforms vector express both SET isoforms and

---

**SET ISOFORMS IN DOGS**

---

1237

---

Fig. 2. Nucleotide sequence alignment of canine SET isoforms. cDNA sequences for canine SET isoforms were aligned using Clustal X2. "*",":" and "." indicate “full,” “strong,” and “weak” conserved residues, respectively. The square indicates the stop codon.

---

Both anti-SET (N-term) and anti-SET (Middle) antibodies exhibited nuclear localization of the endogenous canine SET in CMeC1 cells (Fig. 4B). To determine the localization of individual isoforms, HEK293T cells were transfected to express canine SET isoforms. pLVSIN-EF1α-IRES-ZsGreen canine SET isoforms vector express both SET isoforms and...
ZsGreen fluorescent protein independently, and ZsGreen localizes both in cytosol and nucleus. As shown in Fig. 4C, SETα and β mainly localize in the nucleus, but SETγ and δ localize in both the nucleus and the cytosol.

Because the SET protein directly associates with PP2A to inhibit its activity, we examined whether canine SET isoforms possess the ability to associate with PP2A, using immunoprecipitation (Fig. 5). HEK293T cells were transfected to express canine SET isoforms, and FLAGx3-SET isoforms were immunoprecipitated using anti-FLAG M2 beads and subjected to immunoblotting. Canine SETα and β, but not γ and δ, associated with PP2A, indicating that these 2 isoforms have the ability to suppress PP2A activity.

DISCUSSION

In this study, we found that canine cells express at least 4 SET isoforms, 3 of which are C-terminally truncated. Among them, SETα and β can associate with PP2A, identifying them as endogenous inhibitors. The human SET protein directly binds with PP2A through both its N-terminus and C-terminus regions, and only one of them is sufficient for PP2A association [1]. The Valine 105 residue of human SETα is essential for the association of N-terminus SET. The sequences around this residue are highly conserved in canine SETα and β, but not γ and δ, and may determine the ability for association.

The predicted size of canine SETα, β, γ and δ is 33.5 kDa, 26.1 kDa, 12.6 kDa and 11.9 kDa, respectively. During immunoblotting for endogenous proteins, major bands were observed around 37 kDa in the canine cells. It is possible that these bands correspond to canine SETα, because human SETα, which predicted size is also 33.5 kDa, is detected around 37 kDa. It is also possible that the bands just above 25 kDa correspond to endogenous SETβ. It remains unclear whether SETγ and δ endogenously express, because anti-SET (N-term) did not detect bands corresponding to these isoforms. The bands around 15 kDa observed in the blots for anti-SET (Middle) antibodies are not SETγ and δ. The anti-SET (Middle) antibody cannot recognize SETγ and δ, because the immunogen sequence for this antibody is lost in these 2 isoforms. It may be possible that the ~15-kDa bands observed by the anti-SET (Middle) antibody correspond to N-terminus truncated SET isoforms, which can be expressed by a second open reading frame. We also detected ~50-kDa bands by the anti-SET (Middle) antibody, and it is not clear...
whether these bands correspond to another SET isoform or non-specific binding. Further observations are necessary to clarify this point.

Human SET isoforms are mainly localized in nucleus [14, 20]. Consistent with this, we observed nuclear localization of endogenous canine SET and FLAG-tagged canine SET α and β. It has been reported that human SET has nuclear localization signal in its N-terminus regions [20]. Because canine SET γ and δ localize both in cytosol and nucleus, it is possible that C-terminus region of SET is also important for nuclear localization.

Recently, several studies have reported that SET is an attractive drug target for various human tumors [9, 11, 16]. We have previously reported that COG/OP449 (OncoCide Pharmaceuticals, NC, U.S.A.), a peptide antagonist of SET, recovered PP2A activity and exerted anti-tumor effects on canine lymphoma cells [10]. The effects of OP449 were dependent on SET protein levels, which are now named SETα. However, the present study reveals that canine SETβ is also a potential PP2A inhibitor. OP449 peptides bind to the C-terminal region of SET, which corresponds to 190–290 of
human SETα [7]. Because SETβ does not contain most of this region, it is unclear whether OP449 can antagonize can- nine SETβ functions. This point should be taken into account in future SET-targeting drug development studies in dogs.

ACKNOWLEDGMENTS. This work was partly supported by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (Grant Number 25660227). The funding source had no role in the study design; collection, analysis or interpretation of data; in the writing of the manuscript; or to the decision to submit the manuscript for publication.

REFERENCES

1. Arnaud, L., Chen, S., Liu, F., Li, B., Khatoon, S., Grundke-Iqbal, I. and Iqbal, K. 2011. Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2/PP2A/SET. FEBS Lett. 585: 2653–2659. [Medline] [CrossRef]

2. Arnold, H. K. and Sears, R. C. 2008. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncogenes. Cancer Metastasis Rev. 27: 147–158. [Medline] [CrossRef]

3. Brautigan, D. L. 2013. Protein Ser/Thr phosphatases—the ugly ducklings of cell signalling. FEBS J. 280: 324–345. [Medline] [CrossRef]

4. Carlson, S. G., Eng, E., Kim, E. G., Perlman, E. J., Copeland, T. D. and Ballermann, B. J. 1998. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms’ tumor. J. Am. Soc. Nephrol. 9: 1873–1880. [Medline]

5. Chao, A., Tsai, C. L., Wei, P. C., Hsueh, S., Chao, A. S., Wang, C. J., Tsai, C. N., Lee, Y. S., Wang, T. H. and Lai, C. H. 2010. Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human cho- rioicarcioma. Cancer Lett. 291: 99–107. [Medline] [CrossRef]

6. Christensen, D. J., Chen, Y., Oddo, J., Van Kanegan, M. J., Neil, J., Li, F., Colton, C. A. and Vitek, M. P. 2011. Apolipoprotein E and peptide mimetics modulate inflammation by binding to the SET protein and activating protein phosphatase 2A. J. Immunol. 186: 2535–2542. [Medline] [CrossRef]

7. Cristóbal, I., García-Orti, L., Cirauqui, C., Cortes-Lavaud, X., Garcia-Sánchez, M. A., Calasanz, M. J. and Odero, M. D. 2012. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 97: 543–550. [Medline] [CrossRef]

8. Farrell, A. S., Allen-Petersen, B., Daniel, C. J., Wang, X., Wang, Z., Rodriguez, S., Impy, S., Oddo, J., Vitek, M. P., Lopez, C., Christensen, D. J., Sheppard, B. and Sears, R. C. 2014. Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer. Mol. Cancer Res.; Epub ahead of print. [Medline] [CrossRef]

9. Fujisawa, N., Kawasaki, H., Yabe, R., Christensen, D. J., Vitek, M. P., Mizuno, T., Sato, K. and Ohama, T. 2013. A potential therapeutic application of I2/PP2A inhibitor OP449 for canine T-cell lymphoma. J. Vet. Med. Sci. 75: 349–354. [Medline] [CrossRef]

10. Kubota, D., Yoshida, A., Kawai, A. and Kondo, T. 2014. Proteomics Identified Overexpression of SET Oncogene Product and Possible Therapeutic Utility of Protein Phosphatase 2A in Alveolar Soft Part Sarcoma. J. Proteome Res. 13: 2250–2261. [Medline] [CrossRef]

11. Neviiani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., Mao, H., Chang, J. S., Galietta, A., Uttam, A., Roy, D. C., Valtieri, M., Bruner-Klisovic, R., Caliguri, M. A., Bloomfield, C. D., Marucci, G. and Perrotti, D. 2005. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8: 355–368. [Medline] [CrossRef]

12. Ohama, T. and Brautigan, D. L. 2010. Endotoxin conditioning induces VCP/p97-mediated and inducible nitric-oxide synthase-dependent Tyr284 nitration in protein phosphatase 2A. J. Biol. Chem. 285: 8711–8718. [Medline] [CrossRef]

13. Saddoughi, S. A., Gencer, S., Peterson, Y. K., Ward, K. E., Mukhopadhyay, A., Oaks, J., Bielawski, J., Szuc, Z. M., Thomas, R. J., Selvam, S. P., Senkal, C. E., Garrett-Mayer, E., De Palma, R. M., Fedarovich, D., Liu, A., Habib, A. A., Stahelin, R. V., Perrotti, D. and Ogretmen, B. 2013. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour sup- pression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol. Med. 5: 105–121. [Medline] [CrossRef]

14. Saito, S., Miyaji-Yamaguchi, M., Shiomoya, T. and Nagata, K. 1999. Functional domains of template-activating factor-1 as a protein phosphatase 2A inhibitor. Biochem. Biophys. Res. Com- mun. 259: 471–475. [Medline] [CrossRef]

15. Sobral, L. M., Sousa, L. O., Coletta, R. D., Cabral, H., Greene, L. J., Tajara, E. H., Gutkind, J. S., Curti, C. and Leopoldino, A. M. 2014. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype of Alveolar Soft Part Sarcoma. Cancer Lett. 343: 259–266. [Medline] [CrossRef]

16. Ferrante, A. R., Wang, J. Z., Yu, G., Han, Y., Feng, Y., Xu, Y., Lu, X., Luo, H., Wang, J. Z. and Wang, X. 2013. Ser9 phosphorylation causes cytoplasmic retention of I2/PP2A/SET in Alzheimer disease. Neurobiol. Ag- ing 34: 1748–1758. [Medline] [CrossRef]

17. YABE ET AL.